Search results
Results from the WOW.Com Content Network
The Medicaid Drug Rebate Program is a program in the United States that was created by the Omnibus Budget Reconciliation Act of 1990 (OBRA'90). The program establishes mandatory rebates that drug manufacturers must pay state Medicaid agencies related to the dispensing of outpatient prescription drugs covered by Medicaid .
Empagliflozin, sold under the brand name Jardiance (/ ˈ dʒ ɑːr d i ə n s / JAR-dee-əns), among others, is an antidiabetic medication used to improve glucose control in people with type 2 diabetes.
And Boehringer Ingelheim is making it available to all Americans, regardless of insurance status," Gemmell said. Cyltezo will sell for $550, a 92% discount from the Humira list price of about $7,000.
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies , and the largest private one.
In 2013 Boehringer received clearance for ViSiGi 3D gastric sizing tube for single patient use. This is the first FDA-approved calibration system intended for sleeve gastrectomy. The world's first and only 4-mode suction regulator was introduced in 2015. Boehringer spirometers were selected by the American Medical Research Expedition to Everest.
Senators on the Health, Education, Labor and Pensions committee said Monday that they’d started an investigation into the price of widely used asthma inhalers made by four pharmaceutical ...
On December 30, 2016 Boehringer Ingelheim completed a swap of their OTC business for Sanofi's animal health business. Merial is now owned by Boehringer Ingelheim and combined with their animal health business, Boehringer Ingelheim Vetmedica, to form Boehringer Ingelheim Animal Health.
In June 2016, the company announced that it had struck an asset-swap deal with Boehringer Ingelheim. Sanofi would sell its Merial animal health division (valuing it at €11.4 billion), while acquiring Boehringer's consumer health division (valuing it at €6.7 billion) and €4.7 billion in cash. The deal meant that Sanofi was now one of the ...